Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
Yu Rao(Soochow University), Tao Xue(Huzhou Normal University), Wenxin Du(Zhejiang University), Tianlong Lan(Tsinghua University), Meidan Ying(Zhejiang Cancer Hospital), Xuejing Shao(Jiangsu University), Hongying Gao(Tsinghua University), Xianbin Meng(Tsinghua University), Haiteng Deng(Jiaxing University), Aixiao Xu(Zhejiang University), Tianbai Zhong(Tsinghua University), Wei Wang(Sichuan University), Ting Li(Capital Medical University), Xiuyun Sun(Tsinghua University), Yongbo Liu(South China Agricultural University), Qiaojun He(Zhejiang Lab), Yue Wu(Tsinghua University), Yingqian Chen(Zhejiang University), Bo Yang(Shanghai Jiao Tong University)
Cited by 162
Related Papers
PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
Establishment of mouse expanded potential stem cells
|Nature|2017|308